Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease
| Autor: | T. Bounfour, Antoine Petit, M. Bezier, Jean-David Bouaziz, Martine Bagot, A. Saussine, Michel Rybojad, Florence Cordoliani, C. Juillard |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Dermatology Skin Diseases Gastroenterology Dermatomyositis hemic and lymphatic diseases Internal medicine medicine Humans Clinical efficacy Aged Retrospective Studies Aged 80 and over biology business.industry Immunoglobulins Intravenous Retrospective cohort study Middle Aged medicine.disease Surgery Treatment Outcome Infectious Diseases Muscle disease Intravenous Immunoglobulins biology.protein Female Antibody Headaches medicine.symptom business Skin lesion |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology. 28:1150-1157 |
| ISSN: | 0926-9959 |
| DOI: | 10.1111/jdv.12223 |
| Popis: | Background Treating dermatomyositis (DM) with isolated skin involvement is difficult and inconsistently performed. Intravenous immunoglobulins (IVIg) are recommended for corticoresistant or corticodependant DM, but only a few cases of IVIg use in DM with isolated skin involvement have been reported. Design We performed a retrospective monocentric study of 27 patients who were treated with IVIg for severe DM skin lesions (no or minor muscle involvement) after failure of photoprotection and at least one line of treatment. Results Nineteen patients (70%) exhibited a major response, four patients exhibited a partial response and four patients exhibited no response, including two patients with grade 3 side effects (headaches). The mean number of IVIg courses was 4.8 (range 1–15). Ten patients (53%) relapsed, with a median time of 6.2 months after the last IVIg course. Six of these patients were successfully treated with a new IVIg course. Muscle disease developed in six patients. Conclusion IVIg may be an effective and safe treatment for DM with isolated skin involvement. Relapse occurred frequently, but treatment with a new course of IVIg was successful. Controlled studies are required to confirm these results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text